Literature DB >> 16284444

Successful long-term treatment with once-daily injection of low-dose octreotide in an aged patient with insulinoma.

Takuyuki Katabami1, Hiroyuki Kato, Naoko Shirai, Satoru Naito, Nobuhiko Saito.   

Abstract

The patient was an 83-year-old woman who was admitted to our hospital for evaluation and treatment of chronic hypoglycemia that was first identified 3 years earlier. Serum insulin and C-peptide levels were both elevated during hypoglycemia. Contrast abdominal computed tomography revealed a tumor in the body of the pancreas with blushing during the early phase, and insulinoma was diagnosed. The patient declined surgery because of advanced age, so treatment was started with octreotide, a somatostatin analogue. Hypoglycemia has been successfully controlled with low-dose, once-daily octreotide over 33 months. Few reports have described long-term octreotide administration for benign insulinoma. Moreover, this case is interesting from the perspective of hypoglycemic control using only low-dose, once-daily octreotide. Although somatostatin may induce hypoglycemia in insulinoma, treatment may be useful in patients who are not candidates for surgery, provided that careful monitoring is maintained.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284444     DOI: 10.1507/endocrj.52.629

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  3 in total

Review 1.  Diagnosis and management of insulinoma.

Authors:  Takehiro Okabayashi; Yasuo Shima; Tatsuaki Sumiyoshi; Akihito Kozuki; Satoshi Ito; Yasuhiro Ogawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

2.  Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas.

Authors:  Francesca Marciello; Carolina Di Somma; Michela Del Prete; Vincenzo Marotta; Valeria Ramundo; Annachiara Carratù; Chiara de Luca di Roseto; Luigi Camera; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2014-01-03       Impact factor: 3.633

3.  Metastatic insulinoma managed with radiolabeled somatostatin analog.

Authors:  Ricardo Costa; Rubens Costa; Carlos E Bacchi; Paulo Almeida Filho
Journal:  Case Rep Endocrinol       Date:  2013-12-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.